-
1.发明申请COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR 审中-公开抗抑郁剂类型II抗CD20抗体的联合治疗
公开(公告)号：WO2009053038A3
公开(公告)日：2009-06-25
申请号：PCT/EP2008008919
申请日：2008-10-22
Applicant: HOFFMANN LA ROCHE , GLYCART BIOTECHNOLOGY AG , FERTIG GEORG , FRIESS THOMAS , KLEIN CHRISTIAN , UMANA PABLO
Inventor： FERTIG GEORG , FRIESS THOMAS , KLEIN CHRISTIAN , UMANA PABLO
IPC: A61P35/00 , A61K31/00 , A61K39/395
CPC classification number: A61K39/39558 , A61K31/69 , A61K47/00 , A61K2039/505 , C07K16/2887 , C07K2317/24 , C07K2317/41 , A61K2300/00
Abstract: The present invention is directed to the use an type II anti-CD20 antibody for the manufacture of a medicament for the treatment of cancer, especially of CD20 expressing cancers in combination with a proteasome inhibitor.
Abstract translation: 本发明涉及使用II型抗-CD20抗体来制造用于治疗癌症的药物，特别是与蛋白酶体抑制剂组合的CD20表达癌症的药物。
-
公开(公告)号：WO2007031875A3
公开(公告)日：2007-03-22
申请号：PCT/IB2006/003294
申请日：2006-08-25
Applicant: GLYCART BIOTECHNOLOGY AG , UMANA, Pablo , MOSSNER, Ekkehard
Inventor： UMANA, Pablo , MOSSNER, Ekkehard
IPC: C07K16/28 , C12N15/13 , C12N5/10 , A61K39/395 , A61P35/00
Abstract: The present invention relates to modified antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies or fragments, including chimeric, primatized or humanized antibodies or fragments, having altered ability to mediate cell signaling activity by a target antigen, and/or altered ability to mediate cross-linking of one or more target antigens. In addition, the present invention relates to nucleic acid molecules encoding such modfied ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the modified ABMs of the invention, and to methods of using these modified ABMs in treatment of disease. In addition, the present invention relates to modified ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
-
3.发明申请CD20 ANTIBODIES WITH INCREASED FC RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION 审中-公开CD20抗体与增加的FC受体结合的亲和力和功效
公开(公告)号：WO2005044859A3
公开(公告)日：2005-08-04
申请号：PCT/IB2004003896
申请日：2004-11-05
Applicant: GLYCART BIOTECHNOLOGY AG , UMANA PABLO , BRUENKER PETER , FERRARA CLAUDIA , SUTER TOBIAS , PUENTENER URSULA , MOESSNER EKKEHARD
Inventor： UMANA PABLO , BRUENKER PETER , FERRARA CLAUDIA , SUTER TOBIAS , PUENTENER URSULA , MOESSNER EKKEHARD
CPC classification number: C07K16/2887 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/567 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C07K2319/01 , C12N9/1051 , C12N15/11 , C12N15/63 , C12Y204/01144 , Y10S530/808 , Y10S530/866 , Y10S530/867
Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
Abstract translation: 本发明涉及抗原结合分子（ABM）。 在具体实施方案中，本发明涉及重组单克隆抗体，包括对人CD20特异性的嵌合，灵长类或人源化抗体。 此外，本发明涉及编码这种ABM的核酸分子以及包含该核酸分子的载体和宿主细胞。 本发明还涉及生产本发明的ABM的方法以及使用这些ABM在治疗疾病中的方法。 此外，本发明涉及具有改善的治疗性质的具有改性糖基化的ABM，包括具有增加的Fc受体结合和增加的效应子功能的抗体。
-
4.发明申请ANTIGEN BINDING MOLECULES WITH INCREASED FC RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION 审中-公开具有增强的FC受体结合亲和力和效应功能的抗原结合分子
公开(公告)号：WO2005044859A2
公开(公告)日：2005-05-19
申请号：PCT/IB2004/003896
申请日：2004-11-05
Applicant: GLYCART BIOTECHNOLOGY AG , UMANA, Pablo , BRÜNKER, Peter , FERRARA, Claudia , SUTER, Tobias , PÜNTENER, Ursula , MÖSSNER, Ekkehard
Inventor： UMANA, Pablo , BRÜNKER, Peter , FERRARA, Claudia , SUTER, Tobias , PÜNTENER, Ursula , MÖSSNER, Ekkehard
IPC: C07K16/28
CPC classification number: C07K16/2887 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/567 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C07K2319/01 , C12N9/1051 , C12N15/11 , C12N15/63 , C12Y204/01144 , Y10S530/808 , Y10S530/866 , Y10S530/867
Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
Abstract translation: 本发明涉及抗原结合分子（ABM）。 在具体实施方案中，本发明涉及重组单克隆抗体，包括对人CD20特异性的嵌合，灵长类或人源化抗体。 此外，本发明涉及编码这种ABM的核酸分子以及包含该核酸分子的载体和宿主细胞。 本发明还涉及生产本发明的ABM的方法以及使用这些ABM在治疗疾病中的方法。 此外，本发明涉及具有改善的治疗性质的具有改性糖基化的ABM，包括具有增加的Fc受体结合和增加的效应子功能的抗体。
-
5.发明申请COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT 审中-公开具有抗BCL-2活性剂的II型抗CD20抗体的组合治疗
公开(公告)号：WO2009049841A1
公开(公告)日：2009-04-23
申请号：PCT/EP2008/008635
申请日：2008-10-13
Applicant: F. HOFFMANN-LA ROCHE AG , GLYCART BIOTECHNOLOGY AG , FRIESS, Thomas , KLEIN, Christian , STREIN, Pamela , UMANA, Pablo
Inventor： FRIESS, Thomas , KLEIN, Christian , STREIN, Pamela , UMANA, Pablo
IPC: A61K39/395 , A61P35/00
CPC classification number: A61K39/39558 , A61K31/495 , A61K39/39533 , A61K45/06 , A61K2039/505 , C07K16/2887 , A61K2300/00
Abstract: The present invention is directed to the use of a type II anti-CD20 antibody for the manufacture of a medicament for the treatment of cancer, especially of CD20 expressing cancers in combination with an anti-Bcl-2 active agent.
Abstract translation: 本发明涉及II型抗CD20抗体在制备用于治疗癌症的药物中的用途，特别是与抗Bcl-2活性剂组合的CD20表达癌症的药物。
-
Patent Agency Ranking6.发明申请ANTIGEN BINDING MOLECULES HAVING MODIFIED FC REGIONS AND ALTERED BINDING TO FC RECEPTORS 审中-公开具有改性FC区的抗原结合分子和与FC受体的改变的结合
公开(公告)号：WO2007039818A8
公开(公告)日：2007-11-22
申请号：PCT/IB2006002888
申请日：2006-05-09
Applicant: GLYCART BIOTECHNOLOGY AG , SONDERMANN PETER , FERRARA KOLLER CLAUDIA , BRUNKER PETER , STUART FIONA , UMANA PABLO
Inventor： SONDERMANN PETER , FERRARA KOLLER CLAUDIA , BRUNKER PETER , STUART FIONA , UMANA PABLO
IPC: C07K16/28
CPC classification number: C07K16/2863 , C07K16/2803 , C07K2317/34 , C07K2317/41
Abstract: The present invention is directed to antigen binding molecules, including antibodies, comprising a Fc region having one or more amino acid modifications, wherein the antigen binding molecule exhibits altered binding to one or more Fc receptors as a result of the modification(s). The invention is further directed to polynucleotides and vectors encoding such antigen binding molecules, to host cells comprising the same, to methods for making the antigen binding molecules of the invention, and to their use in the treatment of various diseases and disorders, e.g., cancers.
Abstract translation: 本发明涉及包含具有一个或多个氨基酸修饰的Fc区的抗体结合分子，其中抗原结合分子作为修饰的结果表现出与一个或多个Fc受体的结合改变。 本发明进一步涉及编码这种抗原结合分子的多核苷酸和载体，包含其的宿主细胞，用于制备本发明的抗原结合分子的方法及其在治疗各种疾病和病症例如癌症中的用途 。
-
公开(公告)号：WO2006082515A3
公开(公告)日：2006-08-10
申请号：PCT/IB2006/000238
申请日：2006-02-07
Applicant: GLYCART BIOTECHNOLOGY AG , UMANA, Pablo , MOSSNER, Ekkehard
Inventor： UMANA, Pablo , MOSSNER, Ekkehard
IPC: C07K16/28
Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
-
8.发明申请
公开(公告)号：WO2003011878A3
公开(公告)日：2003-02-13
申请号：PCT/US2002/024739
申请日：2002-08-05
Applicant: GLYCART BIOTECHNOLOGY AG , BAILEY, Sean
Inventor： JEAN-MAIRET, Joel , UMAÑA, Pablo
IPC: C12N5/10
Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.
-
公开(公告)号：WO2009080278A1
公开(公告)日：2009-07-02
申请号：PCT/EP2008/010800
申请日：2008-12-18
Applicant: F. HOFFMANN-LA ROCHE AG , GLYCART BIOTECHNOLOGY AG , ESER, Bianca , KOLL, Hans , REGULA, Joerg, Thomas , SONDERMANN, Peter
Inventor： ESER, Bianca , KOLL, Hans , REGULA, Joerg, Thomas , SONDERMANN, Peter
CPC classification number: G01N33/6857 , C12Q1/34 , C12Q1/37 , G01N2333/96466
Abstract: Antibodies are biological macromolecules which may be subject to modification and degradation processes. A new LC/MS-based method for separating and characterizing antibody-specific degradation products is described in the present application which comprises an enzymatic digestion step to cleave the heavy chain using the enzyme IdeS.
Abstract translation: 抗体是可能经历修饰和降解过程的生物大分子。 在本申请中描述了用于分离和表征抗体特异性降解产物的新的基于LC / MS的方法，其包括使用酶IdeS切割重链的酶消化步骤。
-
10.发明申请ANTIGEN BINDING MOLECULES THAT BIND EGFR, VECTORS ENCODING SAME, AND USES THEREOF 审中-公开结合EGFR的抗原结合分子，编码相同载体的载体及其用途
公开(公告)号：WO2008017963A3
公开(公告)日：2008-11-06
申请号：PCT/IB2007003542
申请日：2007-08-09
Applicant: GLYCART BIOTECHNOLOGY AG , UMANA PABLO , MOSSNER EKKEHARD
Inventor： UMANA PABLO , MOSSNER EKKEHARD
IPC: C07K16/28
CPC classification number: C07K16/464 , C07K16/2863 , C07K2317/24 , C07K2317/565 , C07K2317/567 , C07K2317/72 , C07K2317/732
Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
Abstract translation: 本发明涉及抗原结合分子（ABM）。 在具体的实施方案中，本发明涉及重组单克隆抗体，包括对人EGFR特异的嵌合，灵长类化或人源化抗体。 另外，本发明涉及编码这种ABM的核酸分子，以及包含这种核酸分子的载体和宿主细胞。 本发明还涉及生产本发明的ABM的方法，以及使用这些ABMs治疗疾病的方法。 另外，本发明涉及具有改进的糖基化的ABM，其具有改善的治疗特性，包括具有增加的Fc受体结合和增加的效应功能的抗体。
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.011 seconds)
